Medscape Medical NewsAll articles

Transpara Density 1.0.0

Screenpoint Medical B.V. • Radiology • 12/11/2023

510(k)IEC 62304 Class B
FDA Summary PDF

Device Purpose

Transpara Density 1.0.0 is an artificial intelligence-driven software designed to automatically calculate volumetric breast density, breast volume, and ACR BI-RADS density categories from digital mammography and tomosynthesis images. Its methodology leverages deep learning algorithms operating on processed image data, providing quantitative and categorical outputs to aid healthcare professionals in assessing breast tissue composition, as validated by performance data demonstrating high accuracy, reproducibility, and agreement with radiologist consensus.

Summary

Transpara Density 1.0.0 is a software application that utilizes deep learning artificial intelligence algorithms to automatically assess breast tissue composition from digital mammography (DM) and digital breast tomosynthesis (DBT) images. It analyzes processed 'FOR PRESENTATION' mammography images and synthetic 2D DBT images to determine volumetric breast density (VBD) as a percentage, breast volume in cubic centimeters, and an ACR BI-RADS 5th Edition breast density category (A, B, C, or D). The system is designed to aid healthcare professionals by providing these quantitative and categorical density assessments, functioning as a supportive tool rather than a direct diagnostic aid, and requires integration into a DICOM-compatible software environment for clinical operation. The performance of Transpara Density was rigorously evaluated using a large dataset from over 10,000 women, encompassing images from multiple vendors (GE, Siemens, Hologic, Fujifilm). Accuracy assessments showed strong correlations for VBD when compared against a validated physics-based model (Pearson correlation 0.935) and breast MRI studies (Pearson correlation 0.908). The software demonstrated high reproducibility in VBD measurements between different mammographic views (MLO vs. CC, Pearson 0.947), between the left and right breasts of the same patient (Pearson 0.953), and between DM and DBT modalities (VBD Pearson 0.912). In a study comparing its BI-RADS density categorization against a panel majority vote of eight MQSA-qualified radiologists, Transpara Density achieved 70.8% accuracy for the four density categories and 88.9% accuracy for distinguishing dense versus non-dense breasts, with a corresponding sensitivity of 87.3% and specificity of 90.4%.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Breast densityArtificial intelligenceDeep learningMammographyDigital Breast TomosynthesisVolumetric Breast DensityACR BI-RADSImage processing softwareQuantitative imagingClinical decision support

Device Metadata

Submission Number
K232096
Company
Screenpoint Medical B.V.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the performance of Transpara Density's Volumetric Breast Density (VBD) calculation compare to other commercially available automated breast density assessment tools when using the same imaging datasets?; What is the impact on inter-reader variability among radiologists when Transpara Density's BI-RADS categorization is provided as adjunctive information in clinical practice?; Given that the device utilizes processed 'FOR PRESENTATION' images for mammography and synthetic 2D images for DBT, how sensitive is its performance to variations in image processing parameters across different mammography vendor systems beyond those explicitly tested (GE, Siemens, Hologic, Fujifilm)?; How does Transpara Density's algorithmic approach for density computation using processed images differ fundamentally from methods like the predicate device that utilize raw image data, and what are the implications for accuracy or sensitivity to image acquisition parameters?; What is the potential clinical utility of the 'breast volume in cm3' output, and are there established correlations between this specific measurement provided by Transpara Density and breast cancer risk or other clinical outcomes, independent of VBD and BI-RADS category?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score10/100
SBOM Evidence⚠ Not in summary - likely in full submission per §524B
Cyber Risk Assessment⚠ Not in summary - likely in full submission per §524B
Postmarket Plan⚠ Not in summary - likely in full submission per §524B
§524B ApplicableYes

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials(deep learning, algorithm, dataset)
✓ Detected
SaaSBOMSoftware-as-a-Service Bill of Materials
- Not detected
HBOMHardware Bill of Materials
- Not detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(environment)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of ML-BOM, OBOM detected in AI-generated device summary.

• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.

• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.

• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.

• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Transpara Density 1.0.0 - Screenpoint Medical B.V. | ESL FDA AI Device Intelligence